RQ-3025

N/A

Report date: 2026/05/12 09:09:45

Base Information

Drug NameRQ-3025
Drug Alias NameAlpha/Beta + Omicron BA.2/4/5COVID-19 bivalent mRNA vaccine (Alpha/Beta + Omicron BA.2/4/5) (Yunnan University/Kunming Medical University)RQ-3025
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesYunnan University
China Registration ClassN/A

Develop Information

Active CompaniesYunnan UniversityKunming Medical University
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A